Development and Characterization of Bladder Cancer Patient-Derived Xenografts for Molecularly Guided Targeted Therapy
about
Naturally Occurring Canine Invasive Urinary Bladder Cancer: A Complementary Animal Model to Improve the Success Rate in Human Clinical Trials of New Cancer Drugs.Genomic profiling is predictive of response to cisplatin treatment but not to PI3K inhibition in bladder cancer patient-derived xenografts.The Phosphatidylinositol 3-kinase Pathway as a Potential Therapeutic Target in Bladder Cancer.Co-clinical trials demonstrate predictive biomarkers for dovitinib, an FGFR inhibitor, in lung squamous cell carcinoma.Microdose-Induced Drug-DNA Adducts as Biomarkers of Chemotherapy Resistance in Humans and Mice.Insights from animal models of bladder cancer: recent advances, challenges, and opportunities.Novel theranostic nanoporphyrins for photodynamic diagnosis and trimodal therapy for bladder cancerMicrochamber Cultures of Bladder Cancer: A Platform for Characterizing Drug Responsiveness and Resistance in PDX and Primary Cancer Cells.Orthotopic Mouse Models of Urothelial Cancer.Are we ready to take full advantage of patient-derived tumor xenograft models?Pancreatic Adenocarcinoma Therapeutic Targets Revealed by Tumor-Stroma Cross-Talk Analyses in Patient-Derived Xenografts.Characterization and validation of potential therapeutic targets based on the molecular signature of patient-derived xenografts in gastric cancer.Imaging-guided photo-therapeutic nanoporphyrin synergized HSP90 inhibitor in patient-derived xenograft bladder cancer model.Patient-Derived Bladder Cancer Xenografts.Bladder cancer: Patient-derived murine xenografts.XPO1 inhibition by selinexor induces potent cytotoxicity against high grade bladder malignancies
P2860
Q33593041-DA3956A8-0660-4E48-BFAF-6F4BCE857C72Q37718224-8C237F19-56EF-48C3-B8A1-E32E50EEDB99Q38694934-3C9132BD-AA51-4746-AFD0-6EEB4F4DA37AQ38705330-E95255B0-53C0-4ED4-9AF3-47BB383B8B45Q38728212-4336E108-1631-4337-95A2-EB5560B8E440Q41339763-84C58F00-FBDD-4897-B0EE-0159D1F8FC63Q41634313-069F5F51-8A2B-409C-9DBF-B1992F813335Q42363687-8D953E50-3FEB-49A4-9ABE-7CEA20F13DE7Q47693326-791C28AD-83C9-4A82-AF09-96092C2CBE32Q48099042-B7890089-CCDE-4C8D-9905-A901D92B31B8Q49547506-434BDF5D-DEF0-425A-AC52-AF0D35BE0309Q50057702-9792606E-6181-4AB4-9554-7C196B54EB51Q50113746-1F637FEA-5DED-4B2B-BD32-704B958AF999Q50182625-CBAD0301-F36C-4C6B-A257-B099E85E8487Q55043913-D2DE690C-16AC-4542-A371-9CC9AF471E63Q57818336-69F1874C-B1F0-44F0-A989-0A694A1A0AF1
P2860
Development and Characterization of Bladder Cancer Patient-Derived Xenografts for Molecularly Guided Targeted Therapy
description
2015 nî lūn-bûn
@nan
2015 թուականին հրատարակուած գիտական յօդուած
@hyw
2015 թվականին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Development and Characterizati ...... ularly Guided Targeted Therapy
@ast
Development and Characterizati ...... ularly Guided Targeted Therapy
@en
Development and Characterizati ...... ularly Guided Targeted Therapy
@en-gb
Development and Characterizati ...... ularly Guided Targeted Therapy
@nl
type
label
Development and Characterizati ...... ularly Guided Targeted Therapy
@ast
Development and Characterizati ...... ularly Guided Targeted Therapy
@en
Development and Characterizati ...... ularly Guided Targeted Therapy
@en-gb
Development and Characterizati ...... ularly Guided Targeted Therapy
@nl
prefLabel
Development and Characterizati ...... ularly Guided Targeted Therapy
@ast
Development and Characterizati ...... ularly Guided Targeted Therapy
@en
Development and Characterizati ...... ularly Guided Targeted Therapy
@en-gb
Development and Characterizati ...... ularly Guided Targeted Therapy
@nl
P2093
P2860
P1433
P1476
Development and Characterizati ...... ularly Guided Targeted Therapy
@en
P2093
Carol Bult
Chong-Xian Pan
Clifford G Tepper
Hongyong Zhang
James Keck
Paramita M Ghosh
Parkash Gill
Ralph W de Vere White
Ryan R Davis
Susan Airhart
P2860
P304
P356
10.1371/JOURNAL.PONE.0134346
P407
P577
2015-01-01T00:00:00Z